Compare Harmony Gold Mining Co. (HMY) vs Moderna, Inc. (MRNA) Price & Performance

Harmony Gold Mining (HMY) trades at $14.37, down 1.91% on the day, amid a bearish technical signal and mixed sentiment. The company shows strong fundamentals with a P/E of 9.37, net income margin of 20.06%, and robust cash flow from operations of $15.65 billion in 2024. Recent earnings beat expectations in Q2 2025 but missed in Q4 2025, while revenue grew to $61.38 billion in 2024. A dividend of $0.31 is scheduled for payment in May 2026, adding income appeal.

Outlook is cautious due to technical weakness and analyst skepticism (70% hold rating), but valuation metrics and profitability support potential upside if gold prices stabilize. Key risks include Fed rate sensitivity and operational execution amid the transition to a gold-copper hybrid model. The stock presents a value opportunity with manageable debt, though near-term volatility may persist.

Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.

The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.